Institutional review board approval for this prospective study was obtained from the University of California–San Francisco (UCSF) Committee on Human Research (CHR). The study followed the tenets of the Declaration of Helsinki. Patients were enrolled from the glaucoma service at UCSF from September 16, 2011 to November 30, 2015. Written informed consent was obtained prior to participation.
The study's inclusion criteria for the POAG group included age ≥ 18 years; visually significant cataracts; uncomplicated cataract surgeries without adjunctive procedures (e.g., pupil stretching, use of iris hooks or Malyugin rings); and patients in whom POAG had been determined. Glaucoma in POAG patients had been determined if there was use of glaucoma medications plus one of the following scenarios: (1) visual field loss consistent with glaucoma and cup-to-disc ratio ≥ 0.7 or (2) cup-to-disc ratio ≥ 0.9 if the patient was unable to perform visual field examination in the affected eye.
The exclusion criteria for the POAG group consisted of (1) intraoperative or postoperative complications related to the cataract surgery (e.g., posterior capsule rupture, vitreous loss); (2) history of trabeculectomy or other intraocular glaucoma surgeries; (3) occludable angles with a Shaffer classification grade of 0 or 1 in at least two quadrants; (4) peripheral anterior synechiae (PAS); (5) uveitis, severe retinal diseases, or congenital abnormalities; (6) history of ocular trauma; (7) history of intraocular surgery; and (8) pseudoexfoliation or pigment dispersion. Eyes with history of laser peripheral iridotomy (LPI) or selective laser trabeculoplasty (SLT) were not excluded. Both eyes of a patient were included in the study if they met the criteria.
Inclusion criteria for nonglaucomatous (“control”) patients included age ≥ 18 years; visually significant cataracts; and uncomplicated cataract surgeries without adjunctive procedures. The exclusion criteria included major intraoperative or postoperative complications resulting from cataract surgery; glaucomatous optic neuropathy shown by optic disc cupping or glaucomatous visual field loss; preoperative IOP over 23 mm Hg; the use of glaucoma medications; occludable angles; PAS; uveitis, severe retinal diseases, or congenital abnormalities; history of ocular trauma; history of intraocular surgery; and pseudoexfoliation or pigment dispersion.
The preoperative evaluation, which occurred 1 to 3 weeks before surgery, included complete slit-lamp and fundus examination, ocular biometry measurements, visual acuity testing, gonioscopy, and IOP determination. Intraocular pressure was measured using Goldmann applanation tonometry by the same observer (SCL) in a masked fashion. Two values were obtained, and the mean value was used for analysis. A third value was obtained, and the median value was chosen if the two values differed by more than two points. Gonioscopy was performed using a Zeiss-style 4-mirror goniolens (Model G-4; Volk Optical, Mentor, OH, USA) by the same glaucoma specialist (SCL). Angles were graded in all four quadrants (superior, nasal, temporal, and inferior) based on the Shaffer method. Ocular biometry was obtained with the LENSTAR LS 900 (Haag-Streit, Inc., Koeniz, Switzerland) to measure AL, ACD, LT, and central corneal thickness (CCT).